Incidence of treatment‐related adverse effects ‐ 595‐nm PDL plus verapamil versus verapamil ‐ regrowth ‐ keloid scars ‐ · participants with hypertrophic and keloid scars
It is very uncertain whether laser therapy plus other treatment changes incidence of treatment‐related adverse effects ‐ 595‐nm PDL plus… compared with other treatment (very low certainty).
1 finding from 1 review
RR 1.5 [0.27, 8.22]
Studies not reported
Very low
Incidence of treatment‐related adverse effects ‐ 595‐nm PDL plus verapamil versus verapamil ‐ pain related to treatment ‐ keloid scars ‐ · participants with hypertrophic and keloid scars
It is very uncertain whether laser therapy plus other treatment changes incidence of treatment‐related adverse effects ‐ 595‐nm PDL plus… compared with other treatment (very low certainty).
1 finding from 1 review
RR 3
Studies not reported
Very low
Incidence of treatment‐related adverse effects ‐ 595‐nm PDL plus verapamil versus verapamil ‐ hyperpigmentation ‐ keloid scars ‐ · participants with hypertrophic and keloid scars
It is very uncertain whether laser therapy plus other treatment changes incidence of treatment‐related adverse effects ‐ 595‐nm PDL plus… compared with other treatment (very low certainty).
1 finding from 1 review
RR 5
Studies not reported
Very low
Incidence of treatment‐related adverse effects ‐ 595‐nm PDL plus verapamil versus verapamil ‐ depigmentation ‐ keloid scars ‐ · participants with hypertrophic and keloid scars
It is very uncertain whether laser therapy plus other treatment changes incidence of treatment‐related adverse effects ‐ 595‐nm PDL plus… compared with other treatment (very low certainty).
1 finding from 1 review
RR 1 [0.07, 15.12]
Studies not reported
Very low
Incidence of treatment‐related adverse effects ‐ 595‐nm PDL plus verapamil versus verapamil ‐ purpura ‐ keloid scars ‐ · participants with hypertrophic and keloid scars
It is very uncertain whether laser therapy plus other treatment changes incidence of treatment‐related adverse effects ‐ 595‐nm PDL plus… compared with other treatment (very low certainty).
1 finding from 1 review
RR 15
Studies not reported
Very low
Incidence of treatment‐related adverse effects ‐ 595‐nm PDL plus verapamil versus verapamil ‐ total ‐ keloid scars ‐ · participants with hypertrophic and keloid scars
It is very uncertain whether laser therapy plus other treatment changes incidence of treatment‐related adverse effects ‐ 595‐nm PDL plus… compared with other treatment (very low certainty).
1 finding from 1 review
RR 4.67 [1.53, 14.26]
Studies not reported
Very low
Mortality at 12 months · people living with HIV
It is very uncertain whether rapid antiretroviral therapy (ART) changes mortality at 12 months compared with standard care (very low certainty).
1 finding from 1 review
HIV virological suppression at 6 months (viral load < 400 copies/mL) · people living with HIV
Rapid antiretroviral therapy (ART) probably leads to higher virological suppression at 12 months compared with standard care (moderate certainty).
1 finding from 1 review
Retention in care at 12 months · people living with HIV
Rapid antiretroviral therapy (ART) may leads to higher retention in care at 12 months compared with standard care (low certainty).
1 finding from 1 review
Uptake of ART at 90 days · people living with HIV
Rapid antiretroviral therapy (ART) may leads to higher uptake of ART at 90 days compared with standard care (low certainty).
1 finding from 1 review
Uptake of ART at 12 months · people living with HIV
Rapid antiretroviral therapy (ART) probably leads to higher uptake of ART at 12 months compared with standard care (moderate certainty).
1 finding from 1 review
Treatment modification · people living with HIV
It is very uncertain whether rapid antiretroviral therapy (ART) changes treatment modification compared with standard care (very low certainty).
1 finding from 1 review
Prodromal symptoms: transition to psychosis Endpoint data (events) · people in the prodromal stage of psychosis
It is very uncertain whether group B cognitive behavioural therapy: cognitive behavioural therapy… changes prodromal symptoms: transition to psychosis Long‐term (events) compared with supportive therapy (very low certainty).
1 finding from 1 review
Global state: clinically important change in global state · people in the prodromal stage of psychosis
1 finding from 1 review
Mental state · people in the prodromal stage of psychosis
1 finding from 1 review
Behaviour: clinically important change in behaviour · people in the prodromal stage of psychosis
1 finding from 1 review
Adverse effects: at least one serious adverse event · people in the prodromal stage of psychosis
1 finding from 1 review
Quality of Life Manchester Short Assessment (MANSA) · people in the prodromal stage of psychosis
1 finding from 1 review
Satisfaction and acceptability of treatment (medium term) ‐ leaving the study early · people in the prodromal stage of psychosis
It is very uncertain whether group B cognitive behavioural therapy: cognitive behavioural therapy… changes satisfaction with treatment: leaving the study early Endpoint data… compared with supportive therapy (very low certainty).
1 finding from 1 review
Resolution of daytime urinary incontinence · children aged 5 to 15 years with dysfunctional elimination syndrome, 41/59 with daytime urinary incontinence
It is very uncertain whether pelvic floor muscle training (PFMT) with electromyography… changes resolution of daytime urinary incontinence at 12 months (9 months… compared with pelvic floor muscle training without biofeedback but with standard… (very low certainty).
1 finding from 1 review